<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_diabetic" title="Current Therapeutic Strategies in Diabetic Foot Ulcers" shortTitle="diabetic" author="Aurelio Perez-Favila, Margarita  L Martinez-Fierro, Jessica  G Rodriguez-Lazalde, Miguel  A Cid-Baez, Michelle  de J Zamudio-Osuna, Ma.  del Rosario Martinez-Blanco, Fabiana  E Mollinedo-Montaño, Iram  P Rodriguez-Sanchez, Rodrigo Castañeda-Miranda, Idalia Garza-Veloz" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1010-660X/55/11/714/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
4.	NN	4.
</s>
<s type="frag">
Treatments	NNS	treatment
for	IN	for
Diabetic	JJ	Diabetic
Foot	NNP	Foot
Ulcers	NNS	ulcer
</s>
</head>
<p>
<s type="decl">
One	CD	one
strategy	NN	strategy
for	IN	for
the	DT	the
management	NN	management
of	IN	of
patients	NNS	patient
with	IN	with
a	DT	a
DFU	NNP	DFU
is	VBZ	be
to	TO	to
introduce	VB	introduce
a	DT	a
multidisciplinary	JJ	multidisciplinary
approach	NN	approach
and	CC	and
address	VB	address
the	DT	the
multifactorial	JJ	multifactorial
processes	NNS	process
involved	VBN	involve
in	IN	in
DFUs	NNS	DFU
.	.	.
</s>
<s type="decl">
The	DT	the
use	NN	use
of	IN	of
multi-disciplinary	JJ	multi-disciplinary
teams	NNS	team
(	-LRB-	(
MDTs	NNS	MDT
)	-RRB-	)
that	WDT	that
include	VBP	include
all	DT	all
relevant	JJ	relevant
specialties	NNS	specialty
(	-LRB-	(
i.e.	FW	i.e.
,	,	,
nursing	NN	nursing
,	,	,
orthopedics	NN	orthopedics
,	,	,
plastic	JJ	plastic
surgery	NN	surgery
,	,	,
vascular	JJ	vascular
surgery	NN	surgery
,	,	,
nutrition	NN	nutrition
,	,	,
and	CC	and
endocrinology	NN	endocrinology
departments	NNS	department
)	-RRB-	)
has	VBZ	have
shown	VBN	show
an	DT	a
effect	NN	effect
of	IN	of
decreasing	VBG	decrease
the	DT	the
risks	NNS	risk
associated	VBN	associate
with	IN	with
DFUs	NN	DFU
and	CC	and
amputation	NN	amputation
by	IN	by
50	CD	50
–	SYM	-
85	CD	85
%	NN	%
,	,	,
lowering	VBG	lower
costs	NNS	cost
,	,	,
and	CC	and
leading	VBG	lead
to	IN	to
a	DT	a
better	JJR	good
quality	NN	quality
of	IN	of
life	NN	life
for	IN	for
patients	NNS	patient
with	IN	with
DFUs	NNS	DFU
.	.	.
</s>
</p>
<p>
<s type="decl">
Management	NN	Management
of	IN	of
DFUs	NNS	DFU
requires	VBZ	require
the	DT	the
correct	JJ	correct
classification	NN	classification
of	IN	of
stage	NN	stage
and	CC	and
severity	NN	severity
.	.	.
</s>
<s type="sub">
Adequate	JJ	Adequate
care	NN	care
for	IN	for
DFUs	NNS	DFU
should	MD	should
include	VB	include
a	DT	a
focus	NN	focus
on	IN	on
DM	NNP	DM
control	NN	control
as	RB	as
well	RB	well
as	IN	as
on	IN	on
wound	NN	wind
care	NN	care
,	,	,
proper	JJ	proper
infection	NN	infection
control	NN	control
,	,	,
relieving	VBG	relieve
pressure	NN	pressure
,	,	,
and	CC	and
optimizing	VBG	optimize
blood	NN	blood
flow	NN	flow
.	.	.
</s>
<s type="decl">
The	DT	the
basic	JJ	basic
care	NN	care
for	IN	for
the	DT	the
control	NN	control
and	CC	and
treatment	NN	treatment
of	IN	of
DFUs	NNS	DFU
is	VBZ	be
focused	VBN	focus
on	IN	on
the	DT	the
management	NN	management
of	IN	of
adequate	JJ	adequate
perfusion	NN	perfusion
,	,	,
pressure	NN	pressure
mitigation	NN	mitigation
,	,	,
control	NN	control
of	IN	of
infection	NN	infection
,	,	,
and	CC	and
debridement	NN	debridement
.	.	.
</s>
<s type="decl">
With	IN	with
technological	JJ	technological
advancement	NN	advancement
,	,	,
other	JJ	other
series	NN	series
of	IN	of
therapies	NNS	therapy
for	IN	for
DFUs	NNS	DFU
have	VBP	have
been	VBN	be
implemented	VBN	implement
,	,	,
such	JJ	such
as	IN	as
the	DT	the
development	NN	development
of	IN	of
skin	NN	skin
substitutes	NNS	substitute
,	,	,
negative	JJ	negative
pressure	NN	pressure
wound	NN	wind
therapy	NN	therapy
,	,	,
hyperbaric	JJ	hyperbaric
oxygen	NN	oxygen
,	,	,
the	DT	the
creation	NN	creation
of	IN	of
new	JJ	new
wound	NN	wind
dressings	NNS	dressing
that	WDT	that
include	VBP	include
growth	NN	growth
factors	NNS	factor
,	,	,
and	CC	and
the	DT	the
use	NN	use
of	IN	of
tissues	NNS	tissue
from	IN	from
bioengineering	NN	bioengineering
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
way	NN	way
,	,	,
treatments	NNS	treatment
for	IN	for
DPN	NNP	DPN
,	,	,
PAD	NNP	PAD
,	,	,
and	CC	and
infections	NNS	infection
have	VBP	have
provided	VBN	provide
encouraging	VBG	encourage
results	NNS	result
.	.	.
</s>
</p>
<head>
<s type="frag">
4.1.	CD	4.1.
Treatments	NNS	treatment
for	IN	for
Diabetic	JJ	Diabetic
Peripheral	NNP	Peripheral
Neuropathy	NN	neuropathy
</s>
</head>
<p>
<s type="decl">
DPN	NNP	DPN
is	VBZ	be
a	DT	a
factor	NN	factor
that	WDT	that
increases	VBZ	increase
the	DT	the
risk	NN	risk
of	IN	of
the	DT	the
appearance	NN	appearance
of	IN	of
a	DT	a
DFU	NNP	DFU
,	,	,
owing	VBG	owe
to	IN	to
the	DT	the
loss	NN	loss
of	IN	of
sensation	NN	sensation
in	IN	in
the	DT	the
limb	NN	limb
,	,	,
making	VBG	make
patients	NNS	patient
vulnerable	JJ	vulnerable
to	IN	to
trauma	NN	trauma
.	.	.
</s>
<s type="decl">
Tight	JJ	tight
glycemic	NN	glycemic
control	NN	control
is	VBZ	be
the	DT	the
primary	JJ	primary
step	NN	step
and	CC	and
a	DT	a
main	JJ	main
feature	NN	feature
of	IN	of
DPN	NNP	DPN
management	NN	management
.	.	.
</s>
<s type="decl">
Normoglycemia	NNP	Normoglycemia
is	VBZ	be
more	RBR	more
effectively	RB	effectively
restored	VBN	restore
by	IN	by
a	DT	a
pancreas	NN	pancrea
transplant	NN	transplant
.	.	.
</s>
<s type="decl">
Several	JJ	several
studies	NNS	study
have	VBP	have
demonstrated	VBN	demonstrate
improvement	NN	improvement
of	IN	of
motor	NN	motor
and	CC	and
sensory	NN	sensory
neuropathy	NN	neuropathy
in	IN	in
patients	NNS	patient
with	IN	with
DPN	NNP	DPN
after	IN	after
they	PRP	they
were	VBD	be
treated	VBN	treat
with	IN	with
a	DT	a
pancreas	NN	pancrea
transplant	NN	transplant
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
discrepancies	NNS	discrepancy
exist	VBP	exist
in	IN	in
the	DT	the
time	NN	time
of	IN	of
response	NN	response
.	.	.
</s>
</p>
<p>
<s type="decl">
Pharmacological	JJ	Pharmacological
treatment	NN	treatment
is	VBZ	be
used	VBN	use
for	IN	for
painful	JJ	painful
DPN	NNP	DPN
manifested	VBN	manifest
as	IN	as
numbness	NN	numbness
,	,	,
burning	VBG	burn
,	,	,
stabbing	NN	stabbing
,	,	,
or	CC	or
excruciating	JJ	excruciating
or	CC	or
intractable	JJ	intractable
pain	NN	pain
;	:	;
only	RB	only
three	CD	3
treatments	NNS	treatment
are	VBP	be
approved	VBN	approve
by	IN	by
the	DT	the
U.S.	NNP	U.S.
Food	NNP	Food
and	CC	and
Drug	NNP	Drug
Administration	NNP	Administration
for	IN	for
the	DT	the
pain	NN	pain
associated	VBN	associate
with	IN	with
DPN	NNP	DPN
,	,	,
namely	RB	namely
,	,	,
pregabalin	NN	pregabalin
,	,	,
tapentadol	NN	tapentadol
,	,	,
and	CC	and
duloxetine	NN	duloxetine
.	.	.
</s>
</p>
<p>
<s type="decl">
Another	DT	another
pharmacological	JJ	pharmacological
therapy	NN	therapy
includes	VBZ	include
analgesics	NNS	analgesics
,	,	,
such	JJ	such
as	IN	as
tramadol	NN	tramadol
,	,	,
acetaminophen	NN	acetaminophen
,	,	,
and	CC	and
some	DT	some
opioids	NNS	opioid
such	JJ	such
as	IN	as
oxycodone	NN	oxycodone
,	,	,
which	WDT	which
have	VBP	have
constipation	NN	constipation
and	CC	and
nausea	NN	nausea
as	IN	as
side	NN	side
effects	NNS	effect
,	,	,
and	CC	and
must	MD	must
be	VB	be
taken	VBN	take
with	IN	with
care	NN	care
because	IN	because
they	PRP	they
can	MD	can
be	VB	be
misused	VBN	misuse
.	.	.
</s>
<s type="decl">
Therapy	NN	therapy
with	IN	with
antidepressants	NNS	antidepressant
such	JJ	such
as	IN	as
amitriptyline	NN	amitriptyline
,	,	,
nortriptyline	NN	nortriptyline
,	,	,
and	CC	and
venlafaxine	NN	venlafaxine
,	,	,
among	IN	among
others	NNS	other
,	,	,
has	VBZ	have
shown	VBN	show
an	DT	a
efficacy	NN	efficacy
in	IN	in
neuropathic	JJ	neuropathic
pain	NN	pain
management	NN	management
.	.	.
</s>
<s type="decl">
It	PRP	it
has	VBZ	have
an	DT	a
effect	NN	effect
on	IN	on
the	DT	the
recapture	NN	recapture
of	IN	of
noradrenaline	NN	noradrenaline
and	CC	and
serotonin	NN	serotonin
,	,	,
as	RB	as
well	RB	well
as	IN	as
on	IN	on
muscarinic	JJ	muscarinic
effects	NNS	effect
.	.	.
</s>
<s type="decl">
In	IN	in
spite	NN	spite
of	IN	of
this	DT	this
,	,	,
there	EX	there
are	VBP	be
limited	VBN	limit
studies	NNS	study
evaluating	VBG	evaluate
these	DT	this
drugs	NNS	drug
because	IN	because
their	PRP$	their
doses	NNS	dose
in	IN	in
clinical	JJ	clinical
trials	NNS	trial
are	VBP	be
not	RB	not
entirely	RB	entirely
reproducible	JJ	reproducible
in	IN	in
clinical	JJ	clinical
practice	NN	practice
.	.	.
</s>
</p>
<p>
<s type="decl">
Alpha-lipoic	NN	alpha-lipoic
acid	NN	acid
(	-LRB-	(
ALA	NNP	ALA
)	-RRB-	)
has	VBZ	have
been	VBN	be
suggested	VBN	suggest
as	IN	as
a	DT	a
potential	JJ	potential
therapeutic	JJ	therapeutic
agent	NN	agent
in	IN	in
treating	VBG	treat
DPN	NNP	DPN
;	:	;
its	PRP$	its
antioxidant	NN	antioxidant
capacity	NN	capacity
seems	VBZ	seem
to	TO	to
delay	VB	delay
or	CC	or
reverse	VB	reverse
damages	NNS	damage
to	IN	to
peripheral	JJ	peripheral
nerves	NNS	nerve
.	.	.
</s>
<s type="decl">
Several	JJ	several
human	JJ	human
randomized	VBN	randomize
controlled	VBN	control
trials	NNS	trial
(	-LRB-	(
RCTs	NNS	RCT
)	-RRB-	)
have	VBP	have
investigated	VBN	investigate
the	DT	the
effects	NNS	effect
of	IN	of
ALA	NNP	ALA
in	IN	in
the	DT	the
development	NN	development
of	IN	of
diabetic	JJ	diabetic
nephropathy	NN	nephropathy
.	.	.
</s>
<s type="decl">
A	DT	a
meta-analysis	NN	meta-analysis
of	IN	of
four	CD	4
RCTs	NNS	RCT
(	-LRB-	(
n	NN	n
=	SYM	=
653	CD	653
)	-RRB-	)
showed	VBD	show
that	IN	that
,	,	,
compared	VBN	compare
with	IN	with
placebo	NN	placebo
,	,	,
intravenous	JJ	intravenous
ALA	NNP	ALA
(	-LRB-	(
600	CD	600
mg	NNS	mgillileter
per	IN	per
day	NN	day
)	-RRB-	)
decreased	VBD	decrease
symptoms	NNS	symptom
of	IN	of
neuropathy	NN	neuropathy
when	WRB	when
administered	VBN	administer
for	IN	for
three	CD	3
weeks	NNS	week
,	,	,
but	CC	but
symptom	NN	symptom
improvement	NN	improvement
with	IN	with
oral	JJ	oral
ALA	NNP	ALA
(	-LRB-	(
&gt;600	CD	&gt;600
mg	NN	mgillileter
per	IN	per
day	NN	day
for	IN	for
3	CD	3
–	SYM	-
5	CD	5
weeks	NNS	week
)	-RRB-	)
was	VBD	be
not	RB	not
clinically	RB	clinically
significant	JJ	significant
.	.	.
</s>
<s type="decl">
There	EX	there
is	VBZ	be
no	DT	no
evidence	NN	evidence
evaluating	VBG	evaluate
long-term	JJ	long-term
treatment	NN	treatment
.	.	.
</s>
</p>
<p>
<s type="decl">
Currently	RB	currently
,	,	,
treatments	NNS	treatment
based	VBN	base
on	IN	on
the	DT	the
use	NN	use
of	IN	of
mesenchymal	JJ	mesenchymal
stem	NN	stem
cells	NNS	cell
(	-LRB-	(
MSC	NNP	MSC
)	-RRB-	)
derived	VBN	derive
from	IN	from
adipose	NN	adipose
tissue	NN	tissue
have	VBP	have
been	VBN	be
considered	VBN	consider
as	IN	as
a	DT	a
potential	JJ	potential
treatment	NN	treatment
against	IN	against
DPN	NNP	DPN
.	.	.
</s>
<s type="decl">
These	DT	this
therapies	NNS	therapy
promote	VBP	promote
the	DT	the
production	NN	production
of	IN	of
pro-angiogenic	JJ	pro-angiogenic
,	,	,
neuroprotective	JJ	neuroprotective
,	,	,
and	CC	and
anti-inflammatory	JJ	anti-inflammatory
factors	NNS	factor
,	,	,
which	WDT	which
have	VBP	have
a	DT	a
positive	JJ	positive
impact	NN	impact
on	IN	on
the	DT	the
clinical	JJ	clinical
manifestations	NNS	manifestation
of	IN	of
the	DT	the
disease	NN	disease
.	.	.
</s>
</p>
<p>
<s type="decl">
On	IN	on
the	DT	the
other	JJ	other
hand	NN	hand
,	,	,
the	DT	the
use	NN	use
of	IN	of
biological	JJ	biological
therapy	NN	therapy
with	IN	with
low	JJ	low
doses	NNS	dose
of	IN	of
IL-6	NNP	IL-6
has	VBZ	have
been	VBN	be
demonstrated	VBN	demonstrate
to	TO	to
promote	VB	promote
improvement	NN	improvement
of	IN	of
blood	NN	blood
flow	NN	flow
,	,	,
decrease	VB	decrease
chronic	JJ	chronic
inflammation	NN	inflammation
,	,	,
and	CC	and
regenerate	VB	regenerate
peripheral	JJ	peripheral
nerve	NN	nerve
fibers	NNS	fiber
.	.	.
</s>
<s type="decl">
Accordingly	RB	accordingly
,	,	,
IL-6	NNP	IL-6
may	MD	may
prove	VB	prove
to	TO	to
be	VB	be
an	DT	a
effective	JJ	effective
treatment	NN	treatment
for	IN	for
the	DT	the
protection	NN	protection
and/or	NN	and/or
restoration	NN	restoration
of	IN	of
peripheral	JJ	peripheral
nerve	NN	nerve
function	NN	function
in	IN	in
DPN	NNP	DPN
;	:	;
see	VB	see
Table	NNP	Table
1	CD	1
.	.	.
</s>
</p>
<head>
<s type="frag">
4.2.	CD	4.2.
Treatments	NNS	treatment
for	IN	for
Peripheral	NNP	Peripheral
Arterial	NNP	Arterial
Disease	NNP	Disease
(	-LRB-	(
Ischemia	NNP	Ischemia
)	-RRB-	)
</s>
</head>
<p>
<s type="sub">
Ischemia	NNP	Ischemia
presenting	VBG	present
in	IN	in
diabetic	JJ	diabetic
patients	NNS	patient
due	JJ	due
to	IN	to
a	DT	a
reduction	NN	reduction
in	IN	in
blood	NN	blood
flow	NN	flow
that	WDT	that
occurs	VBZ	occur
in	IN	in
both	CC	both
small	JJ	small
vessels	NNS	vessel
(	-LRB-	(
microvascular	JJ	microvascular
,	,	,
such	JJ	such
as	IN	as
capillaries	NNS	capillary
)	-RRB-	)
and	CC	and
large	JJ	large
vessels	NNS	vessel
(	-LRB-	(
macrovascular	JJ	macrovascular
,	,	,
such	JJ	such
as	IN	as
arteries	NNS	artery
and	CC	and
veins	NNS	vein
)	-RRB-	)
,	,	,
or	CC	or
due	JJ	due
to	IN	to
a	DT	a
decrease	NN	decrease
of	IN	of
angiogenesis	NN	angiogenesis
,	,	,
can	MD	can
be	VB	be
treated	VBN	treat
through	IN	through
revascularization	NN	revascularization
of	IN	of
at	IN	at
least	JJS	least
one	CD	one
of	IN	of
the	DT	the
foot	NN	foot
arteries	NNS	artery
to	TO	to
try	VB	try
to	TO	to
restore	VB	restore
blood	NN	blood
flow	NN	flow
in	IN	in
patients	NNS	patient
with	IN	with
a	DT	a
DFU	NN	DFU
whose	WP$	whose
toe	NN	toe
pressure	NN	pressure
is	VBZ	be
&lt;30	CD	&lt;30
mmHg	NN	mmHg
or	CC	or
transcutaneous	JJ	transcutaneous
oxygen	NN	oxygen
pressure	NN	pressure
(	-LRB-	(
TcPO2	NNP	TcPO2
)	-RRB-	)
&lt;25	CD	&lt;25
mmHg	NN	mmHg
,	,	,
as	RB	as
well	RB	well
as	IN	as
in	IN	in
those	DT	this
who	WP	who
have	VBP	have
a	DT	a
DFU	NN	DFU
that	WDT	that
does	VBZ	do
not	RB	not
heal	VB	heal
with	IN	with
pressure	NN	pressure
on	IN	on
the	DT	the
ankle	NN	ankle
of	IN	of
&lt;50	CD	&lt;50
mmHg	NN	mmHg
or	CC	or
ankle-brachial	JJ	ankle-brachial
index	NN	index
(	-LRB-	(
ABI	NNP	ABI
)	-RRB-	)
&lt;0.5	CD	&lt;0.5
.	.	.
</s>
</p>
</text>